Miravo Healthcare(TM) to Present at Q1 Virtual Investor Summit

Tuesday, March 8, 2022 - 2:00 p.m. ET

Mississauga, Ontario--(Newsfile Corp. - February 28, 2022) - Nuvo Pharmaceuticals Inc. (TSX: MRV) (OTCQX: MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced Jesse Ledger, Miravo's President & Chief Executive Officer and Mary-Jane Burkett, Miravo's Vice President & Chief Financial Officer will be presenting at the Q1 Virtual Investor Summit.

Event: Q1 Virtual Investor Summit

Date: Tuesday, March 8, 2022

Time: 2:00 p.m. ET

Presentation Link: https://us06web.zoom.us/webinar/register/WN_8srbw2cDQCm272PA5BjSeg

About the Investor Summit

The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. The Q1 Investor Summit will take place virtually, featuring 90+ companies and over 500 investors comprising institutional investors, family offices, and high net worth investors. Sectors Participating: Biotech, Communication Services, Consumer, Energy, Energy/Tech, Financial, Healthcare, Industrials, Materials, Real Estate, Technology, and Tech/Crypt. Contact: [email protected]

About Miravo Healthcare

Miravo is a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products. The Company's products target several therapeutic areas, including pain, allergy, neurology and dermatology. The Company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets. Miravo's head office is located in Mississauga, Ontario, Canada, the international operations are located in Dublin, Ireland and the Company's manufacturing facility is located in Varennes, Québec, Canada. The Varennes facility operates in a Good Manufacturing Practices (GMP) environment respecting the U.S., Canada and E.U. GMP regulations and is regularly inspected by Health Canada and the U.S. Food and Drug Administration. For additional information, please visit www.miravohealthcare.com.

FOR MORE INFORMATION, PLEASE CONTACT:

Investor Relations
Stefan Eftychiou
905 326 1888 ext 60
[email protected]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/114550

You May Also Be Interested In

• Elliott targets Deutsche Telekom, opposes $300B T-Mobile merger - Bloomberg News
• Simply Good Foods Company Securities Fraud Class Action Result of Undisclosed Acquisition Failures and Over 27% Stock Decline - Investors May Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC
• Lotus Creek Exploration Inc. Announces Wilson Creek Operational Update and July Update to Shareholders